Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations
Rituximab is a chimeric (mouse and human) monoclonal antibody against B-lymphocytes (CD20). This drug is widely used in rheumatology in the treatment of rheumatoid arthritis, Sjogren’s syndrome, some systemic connective tissue diseases and vasculitis, as well as in hematology in lymphoproliferative...
Saved in:
Main Authors: | T. S. Panevin, E. G. Zotkin, E. A. Troshina, G. V. Lukina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2023-10-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3410 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of rituximab in the of immunoinflammatory rheumatic diseases combined with Graves' disease (autoimmune polyglandular syndrome in adults): case report and literature review
by: T. S. Panevin, et al.
Published: (2024-10-01) -
Transforming growth factor β1 (TGF-β1) in patients with endocrine ophthalmopathy and Graves’ disease: A predictor of treatment efficiency
by: N. Yu. Sviridenko, et al.
Published: (2022-11-01) -
Practical Guidelines Management of Graves Ophthalmopathy
by: Imam Subekti, et al.
Published: (2020-02-01) -
Practical Guidelines Management of Graves Ophthalmopathy
by: Imam Subekti, et al.
Published: (2020-02-01) -
Explore the Possibility of Early Clinical Diagnosis of Endocrine Ophthalmopathy Based on Eye Symptoms of Hyperthyroidism
by: V. G. Likhvantseva, et al.
Published: (2016-12-01)